Cerebrospinal fluid alterations of the serotonin product, 5-hydroxyindolacetic acid, in neurological disorders

Elisa De Grandis, Mercedes Serrano, Belén Pérez-Dueñas, Aida Ormazábal, Raquel Montero, Edvige Veneselli, Mercè Pineda, Verónica González, Francesc Sanmartí, Carmen Fons, Anna Sans, Bru Cormand, Luis Puelles, Antonia Alonso, Jaime Campistol, Rafael Artuch, Angels García-Cazorla

Research output: Contribution to journalArticle

Abstract

Although patients with low cerebrospinal fluid (CSF) serotonin metabolite levels have been reported, inborn errors of the rate-limiting enzyme of serotonin synthesis (tryptophan hydroxylase, TPH) have not been described so far. In this study we aimed to evaluate CSF alterations of the serotonin metabolite 5-hydroxyindolacetic acid (5-HIAA) in patients with neurological disorders and to explore a possible TPH deficiency in some of them. A total of 606 patients (286 males, 320 females, mean age 4 years and 6 months, SD 5 years and 7 months) underwent CSF analysis of neurotransmitter metabolites by reverse phase high performance liquid chromatography. Results were compared with values established in a control population. Patients' medical records were reviewed to determine diagnosis and clinical features. A primary defect of biogenic amines was genetically investigated in indicated patients. Low 5-HIAAwas seen in 19.3%. Of these, 22.2% showed inborn errors of metabolism (mitochondrial disorders being the most frequent at 10.2% of low 5-HIAA patients) and neurogenetic conditions. Other relatively frequent conditions were pontocerebellar hypoplasia (4.3%), Rett syndrome (4.3%), and among congenital nonetiologically determined conditions, epilepsy including epileptic encephalopathies (26.4%), leukodystrophies (6.8%), and neuropsychiatric disturbances (4.2%). Mutational analysis of the TPH2 gene, performed in five candidate patients, was negative. Although frequency of secondary alteration of 5-HIAA was relatively high in patients with neurological disorders, this finding was more frequently associated with some neurometabolic disorders, epileptic encephalopathies, and neuropsychiatric disturbances. No inborn errors of TPH were found. Due to serotonin's neurotrophic role and to ameliorate symptoms, a supplementary treatment with 5-hydroxytriptophan would seem advisable in these patients.

Original languageEnglish
Pages (from-to)803-809
Number of pages7
JournalJournal of Inherited Metabolic Disease
Volume33
Issue number6
DOIs
Publication statusPublished - Dec 2010

ASJC Scopus subject areas

  • Genetics(clinical)
  • Genetics

Fingerprint Dive into the research topics of 'Cerebrospinal fluid alterations of the serotonin product, 5-hydroxyindolacetic acid, in neurological disorders'. Together they form a unique fingerprint.

  • Cite this

    De Grandis, E., Serrano, M., Pérez-Dueñas, B., Ormazábal, A., Montero, R., Veneselli, E., Pineda, M., González, V., Sanmartí, F., Fons, C., Sans, A., Cormand, B., Puelles, L., Alonso, A., Campistol, J., Artuch, R., & García-Cazorla, A. (2010). Cerebrospinal fluid alterations of the serotonin product, 5-hydroxyindolacetic acid, in neurological disorders. Journal of Inherited Metabolic Disease, 33(6), 803-809. https://doi.org/10.1007/s10545-010-9200-9